Attgeno Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.44M

  • Investors
  • 8

Attgeno General Information

Description

Developer of nitric oxide-donating drugs designed to selectively treat acute blood pressure in the lungs. The company's drug is a blood vessel-inducing pharmaceutical based on nitric oxide-containing substances with unique properties that pass through the blood to the lungs and lower the pressure in the lung cycle by locally extending the blood vessels, enabling doctors to treat the life-threatening condition of their patients.

Contact Information

Website
www.attgeno.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Fogdevreten 2A
  • 171 65 Solna
  • Sweden
+46 070-645
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • Fogdevreten 2A
  • 171 65 Solna
  • Sweden
+46 070-645

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Attgeno Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 26-Oct-2023 $1.44M Completed Clinical Trials - Phase 2
7. Later Stage VC 01-Jul-2022 Completed Clinical Trials - Phase 2
6. Later Stage VC 01-Jan-2021 Completed Generating Revenue
5. Grant 01-Oct-2020 Completed Clinical Trials - Phase 1
4. Later Stage VC 01-Apr-2020 Completed Clinical Trials - Phase 1
3. Later Stage VC 22-May-2018 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2017 Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Attgeno’s complete valuation and funding history, request access »

Attgeno Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
Preference
Preference 36,750 $53.99 $53.99 1x $53.99 13.03%
Preference 93,562 $33.88 $33.88 1x $33.88 33.17%
To view Attgeno’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Attgeno Patents

Attgeno Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024260728-A1 Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease Pending 27-Apr-2023
EP-4701632-A1 Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease Pending 27-Apr-2023
WO-2024223950-A1 Mono- and bis-nitrosylated propanediols for use in the treatment of a thromboembolic disease Inactive 27-Apr-2023
GB-202306258-D0 New medical uses Inactive 27-Apr-2023
JP-7943286-B2 Mono and bisnitrosylated propanediols for therapeutic use Active 27-May-2020 A61K31/04
To view Attgeno’s complete patent history, request access »

Attgeno Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Attgeno Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arbona PE/Buyout Minority
Eir Ventures Venture Capital Minority
Medtech4Health Not-For-Profit Venture Capital
SWElife Government
Vinnova Government
You’re viewing 5 of 8 investors. Get the full list »

Attgeno FAQs

  • When was Attgeno founded?

    Attgeno was founded in 2005.

  • Where is Attgeno headquartered?

    Attgeno is headquartered in Solna, Sweden.

  • What is the size of Attgeno?

    Attgeno has 8 total employees.

  • What industry is Attgeno in?

    Attgeno’s primary industry is Drug Discovery.

  • Is Attgeno a private or public company?

    Attgeno is a Private company.

  • What is the current valuation of Attgeno?

    The current valuation of Attgeno is .

  • What is Attgeno’s current revenue?

    The current revenue for Attgeno is .

  • How much funding has Attgeno raised over time?

    Attgeno has raised $12.9M.

  • Who are Attgeno’s investors?

    Arbona, Eir Ventures, Medtech4Health, SWElife, and Vinnova are 5 of 8 investors who have invested in Attgeno.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process